Catalyst Repository | Zosano Pharma Corporation Common Stock

Zosano Pharma Corporation Common Stock

(NASDAQ:ZSAN)

Description

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

ZSAN Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$1.2500
Previous Close Volume
3893212